Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.37 |
| ▸ | FLT3 | P36888 | 7/20 | 0.37 |
| ▸ | CDK1 | P06493 | 6/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.37 |
| ▸ | AXL | P30530 | 5/20 | 0.37 |
| ▸ | FLT4 | P35916 | 5/20 | 0.37 |
| ▸ | CLK2 | P49760 | 5/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 5/20 | 0.37 |
| ▸ | CAMK2B | Q13554 | 5/20 | 0.37 |
| ▸ | CAMK2G | Q13555 | 5/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 5/20 | 0.37 |
| ▸ | PTK6 | Q13882 | 5/20 | 0.37 |
| ▸ | NTRK3 | Q16288 | 5/20 | 0.37 |
| ▸ | PKN2 | Q16513 | 5/20 | 0.37 |
| ▸ | MINK1 | Q8N4C8 | 5/20 | 0.37 |
| ▸ | PRKD2 | Q9BZL6 | 5/20 | 0.37 |
| ▸ | SLK | Q9H2G2 | 5/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8941173 | 0.91 | BTK (0.37) | BTKFLT3CDK1NTRK1PRKD3 | |
| SCHEMBL8940737 | 0.91 | NTRK1 (0.44) | BTKFLT3CDK1NTRK1PRKD3 | |
| SCHEMBL8941504 | 0.89 | BTK (0.40) | BTKFLT3CDK1NTRK1PRKD3 | |
| SCHEMBL8940851 | 0.89 | BTK (0.48) | BTKJAK3BMXPLCG1 | |
| SCHEMBL8940562 | 0.88 | BTK (0.41) | BTKFLT3CDK1NTRK1PRKD3 | |
| SCHEMBL8941141 | 0.88 | FLT3 (0.38) | BTKFLT3CDK1NTRK1PRKD3 | |
| SCHEMBL8941638 | 0.88 | BTK (0.40) | BTKFLT3CDK1NTRK1PRKD3 | |
| SCHEMBL8940789 | 0.88 | BTK (0.39) | BTKFLT3CDK1NTRK1PRKD3 | |
| SCHEMBL8941676 | 0.88 | NTRK1 (0.38) | BTKFLT3CDK1NTRK1PRKD3 | |
| SCHEMBL8940785 | 0.88 | BTK (0.39) | BTKFLT3CDK1NTRK1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-8987454-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-03-24 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722889-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-13 | — | — | US | disclosed |
| US-8501446-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-11 | — | — | US | disclosed |
| US-8188281-B2 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507826-B2 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258958-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | BTK 29/4885FLT3 310/4885CDK1 45/4885 |
| US-20090176763-A1 | Azaindoles useful as inhibitors of JAK and other protein kinases | JAK3, JAK2, JAK1 | BTK 29/4885FLT3 310/4885CDK1 45/4885 |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | BTK 29/4885FLT3 310/4885CDK1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.